Select country set
language
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

hsa-miR-140-3p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


Clearance sale RDM0056H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Whole blood, PBMC, Cell culture lysates

Sample Requirements

10 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

6.5 – 0.02 amol/μl

Limit of Detection

0.07 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 5.8%

Inter-assay (Run-to-Run)

n = 5,
CV = 6.4%

Spiking Recovery

98.4%

Dilution Linearity

99.7%

Specificity

Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.

Note

Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.


Product Manual: miREIA - microRNA enzyme immunoassay

 

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-140-3p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Oncology, Others

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in the pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

MiR-140 is encoded within intron 16 of Wwp2, an E3 ubiquitin ligase. It was first identified as a key player in cartilage development and homeostasis in chondrocytes. The regulation of miR-140 was reported to be tissue-dependent. Besides its role in chondrocytes, it was found to be expressed in numerous other tissues and cell types including brain, breast, lung, colon, ovary and testis.

Importantly, expression-profiling experiments revealed a potential tumor suppressor function for miR-140 in many cancers where its expression was found to be downregulated in cutaneous squamous cell carcinoma, basal cell carcinoma, osteosarcoma, breast cancer, ovarian cancer, bladder cancer, gastric cancer, colon cancer and lung squamous cell carcinoma. Inversely, it was revealed a correlation between miR 140-3p overexpression with chordoma invasion and recurrence suggesting poor prognosis of spinal chordoma. miR-140 also has been demonstrated to be associated with progression of many conditions including renal cell carcinoma or osteoarthritis. In addition, miR 140-3p is found to be ectopic and implicated in proliferation, migration and invasion in NSCLC cells. It was reported that the level of plasma exosomal miR 140-3p in colorectal cancer (CRC) patients was lower than that in healthy controls. The decreased miR-140-3p level was also observed in CRC patients with liver metastasis. The expression of miR 140-3p in CRC tissues were significantly lower than that in matched normal tissues. Functionally, miR 140-3p overexpression suppressed proliferation, migration, invasion, and β-catenin nuclear translocation, as well as promoted apoptosis in LoVo cells, while inhibition of miR-140-3p reversed these cellular processes in HCT 116 cells.

Summary References (10)

References to miR-140-3p

  • Miyaki S, Sato T, Inoue A, Otsuki S, Ito Y, Yokoyama S, Kato Y, Takemoto F, Nakasa T, Yamashita S, et al. MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev. 2010;24(11):1173–85.
  • Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene. 2009;28(46):4065–74.
  • Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67(18):8699–707.
  • Sand M, Skrygan M, Sand D, Georgas D, Hahn SA, Gambichler T, Altmeyer P, Bechara FG. Expression of microRNAs in basal cell carcinoma. Br J Dermatol. 2012;167(4):847–55
  • Zou MX, Huang W, Wang XB, Lv GH, Li J, Deng YW. Identification of miR-140-3p as a marker associated with poor prognosis in spinal chordoma. Int J Clin Exp Pathol. 2014;7(8):4877–85.
  • Zhou Y, Wang B, Wang Y, Chen G, Lian Q, Wang H. miR-140-3p inhibits breast cancer proliferation and migration by directly regulating the expression of tripartite motif 28. Oncol Lett 2019 Apr;17(4):3835-3841.
  • Guan L, Tan J, Li H and Jin X. Biomarker identification in clear cell renal cell carcinoma based on miRNA-seq and digital gene expression-seq data. Gene 2018,647 205–212
  • Ntoumou E, Tzetis M, Braoudaki M, Lambrou G, Poulou M, Malizos K, Stefanou N, Anastasopoulou L, et al. Serum microRNA array analysis identifies miR-140-3p, miR-33b-3p and miR-671-3p as potential osteoarthritis biomarkers involved in metabolic processes. Clin. Epigenetics 2017 ,9 127.
  • Kong X, Zhang G, Huo Y, Zhao X, Cao D, Guo S, Li A and Zhang X. MicroRNA-140–3p inhibits proliferation, migration and invasion of lung cancer cells by targeting ATP6AP2. Int. J. Clin. Exp. Pathol. 2015,8 12845–12852.
  • Liu D, Chen C, Cui M, Zhang H. miR-140-3p inhibits colorectal cancer progression and its liver metastasis by targeting BCL9 and BCL2. Cancer Med. 2021 May;10(10):3358-3372.
Related Products Docs